Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 3;56(3):2000673.
doi: 10.1183/13993003.00673-2020. Print 2020 Sep.

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension

Olivier Sitbon  1 , Vincent Cottin  2 , Matthieu Canuet  3 , Pierre Clerson  4 , Virginie Gressin  5 , Loïc Perchenet  5 , Laurent Bertoletti  6   7 , Hélène Bouvaist  8 , François Picard  9 , Grégoire Prévot  10 , Emmanuel Bergot  11 , Gérald Simonneau  12
Affiliations

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension

Olivier Sitbon et al. Eur Respir J. .

Abstract

Initial combination therapy with macitentan and tadalafil is well tolerated and improves cardiopulmonary haemodynamics and functional capacity in newly diagnosed PAH patients https://bit.ly/3aWZagH

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: O. Sitbon reports personal fees from Actelion Pharmaceuticals France Ltd for steering committee work and non-financial editorial support from Actelion Pharmaceuticals Ltd, during the conduct of the study; grants, personal fees for advisory board work, consultancy, steering committee work and lectures, and non-financial editorial support from Actelion Pharmaceuticals Ltd and GlaxoSmithKline, grants and personal fees for advisory board work, consultancy and lectures from Bayer HealthCare and Merck, personal fees for consultancy and advisory board work from Arena Pharmaceuticals, personal fees for advisory board work from Gossamer Bio and Ferrer, outside the submitted work. Conflict of interest: V. Cottin reports non-financial editorial support from Actelion Pharmaceuticals Ltd, personal fees for steering committee work from Actelion Pharmaceuticals France Ltd, during the conduct of the study; personal fees for advisory board work and lectures, and non-financial travel support from Actelion Pharmaceuticals Ltd, grants, personal fees for consultancy and lectures, and non-financial travel support from Boehringer Ingelheim and Roche, personal fees for advisory board and data monitoring committee work from Bayer/MSD and Galapagos, personal fees for adjudication committee work from Gilead, personal fees for advisory board work and lectures from Novartis, personal fees for lectures from Sanofi, personal fees for data monitoring and steering committee work from Promedior, personal fees for data monitoring committee work from Celgene and Galecto, outside the submitted work. Conflict of interest: M. Canuet reports non-financial editorial support from Actelion Pharmaceuticals Ltd, personal fees for steering committee work from Actelion Pharmaceuticals France Ltd, during the conduct of the study; personal fees for consultancy from Actelion Pharmaceuticals Ltd, outside the submitted work. Conflict of interest: P. Clerson reports non-financial editorial support from Actelion Pharmaceuticals Ltd, during the conduct of the study. Conflict of interest: V. Gressin reports non-financial editorial support from Actelion Pharmaceuticals Ltd, was an employee of Actelion Pharmaceuticals France Ltd during the conduct of the study, has RSU in parent company Johnson and Johnson, and owns shares in Idorsia Pharmaceuticals Ltd. Conflict of interest: L. Perchenet reports non-financial editorial support from Actelion Pharmaceuticals Ltd, during the conduct of the study; and is an employee of Actelion Pharmaceuticals Ltd. Conflict of interest: L. Bertoletti reports non-financial editorial support from Actelion Pharmaceuticals Ltd, during the conduct of the study; non-financial support for travel and advisory board work from Actelion Pharmaceuticals Ltd, personal fees for advisory board work and non-financial support for travel from Bayer, non-financial support for travel from Pfizer, personal fees for advisory board work from Daichii-Sankyo, outside the submitted work. Conflict of interest: H. Bouvaist reports non-financial editorial support from Actelion Pharmaceuticals Ltd, during the conduct of the study. Conflict of interest: F. Picard reports non-financial editorial support from Actelion Pharmaceuticals Ltd, personal fees for steering committee work from Actelion Pharmaceuticals France Ltd, during the conduct of the study; personal fees and non-financial support from Novartis, outside the submitted work. Conflict of interest: G. Prévot reports non-financial editorial support from Actelion Pharmaceuticals Ltd, personal fees for steering committee work from Actelion Pharmaceuticals France Ltd, during the conduct of the study. Conflict of interest: E. Bergot reports non-financial editorial support from Actelion Pharmaceuticals Ltd, personal fees for steering committee work from Actelion Pharmaceuticals France Ltd, during the conduct of the study; personal fees for advisory board work and lectures from Chiesi Pharmaceuticals, Actelion Pharmaceuticals Ltd, Boehringer Ingelheim, Roche, Novartis and AstraZeneca, outside the submitted work. Conflict of interest: G. Simonneau reports non-financial editorial support from Actelion Pharmaceuticals Ltd, personal fees for steering committee work and non-financial travel/accommodation support from Actelion Pharmaceuticals France Ltd, during the conduct of the study; grants, personal fees for consultancy and lectures and non-financial travel/accommodation support from Actelion Pharmaceuticals Ltd, grants, personal fees for consultancy, steering committee work and lectures, and non-financial travel/accommodation support from Bayer Healthcare, personal fees for consultancy and lectures and non-financial travel/accommodation support from MSD and Acceleron, outside the submitted work.

References

    1. Galiè N, Barbera JA, Frost AE, et al. . Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834–844. doi:10.1056/NEJMoa1413687 - DOI - PubMed
    1. Galiè N, Humbert M, Vachiéry JL, et al. . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 2016; 37: 67–119. doi:10.1093/eurheartj/ehv317 - DOI - PubMed
    1. Galiè N, Humbert M, Vachiéry JL, et al. . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J 2015; 46: 903–975. doi:10.1183/13993003.01032-2015 - DOI - PubMed
    1. Galiè N, Channick RN, Frantz RP, et al. . Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019; 53: 1801889. doi:10.1183/13993003.01889-2018 - DOI - PMC - PubMed
    1. Pulido T, Adzerikho I, Channick RN, et al. . Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809–818. doi:10.1056/NEJMoa1213917 - DOI - PubMed

Publication types

LinkOut - more resources